By Connor Hart
Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body produces too much cortisol.
The Redwood City, Calif., company said Monday its application is based on positive results observed in patients receiving the treatment, relacorilant, in both recent and continuing trials.
"Patients in these studies who received relacorilant experienced improvements in a wide array of hypercortisolism's signs and symptoms, with an acceptable safety burden," the company said.
Chief Executive Joseph Belanoff said the drug's combination of efficacy and safety gives it the potential to become the standard of care for the medical treatment of patients with hypercortisolism.
Cortisol, which is sometimes called the stress hormone, helps to maintain blood pressure, regulate blood sugar, reduce inflammation and convert food into energy. In excessive amounts cortisol can cause health problems including high blood pressure, obesity, elevated blood sugar, severe fatigue and behavior disturbances.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 30, 2024 17:48 ET (22:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.